M Mirochnick 1, A Stek 2, EV Capparelli 3, B Best 3, D Holland 3, J Connor 3, SK Burchett 4, C Hu 5, E Smith 6, JS Read 7, and PACTG 1026s Protocol Team.

Slides:



Advertisements
Similar presentations
Challenges to Pediatric Antiretroviral Treatment Elaine Abrams, David Hoos MTCT-Plus.
Advertisements

Effects of Physiologic Testosterone Supplementation on Fat Mass and Distribution in HIV-Infected Men with Abdominal Obesity CM Shikuma, RA Parker, F Sattler,
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
PMTCT FAILURE: THE ROLE OF MATERNAL AND FACILITY –RELATED FACTORS ICASA Presentation 8 th to 12 th Dec 2013 Onono Maricianah 1, Elizabeth A. Bukusi 1,
1 Effect of Maternal HAART on Postnatal HIV-1 Transmission after Cessation of Extended Infant Antiretroviral Prophylaxis Taha Taha 1, Johnstone Kumwenda.
Phase 1/2, Multicenter, Open-label, Pharmacokinetic, Safety, Tolerability, and Antiviral Activity Study of Dolutegravir (DTG), a Novel Integrase Inhibitor,
Principles of care of the HIV-1 infected pregnant mother Protection of mothers from mono- and dual- therapies likely to induce resistance: Women refusing.
Once-Daily Regimen of FTC, DDI, EFV in ARV Therapy- Naïve Children PACTG 1021.
American Conference on Pharmacometics –San Diego, CA; April Population PK modeling incorporating enzyme induction mechanism to guide the design.
Perinatal HIV Case Series Reports for Births in Presenter: Elvia Ledezma Texas Department of State Health Services.
PROMISE Introduction to PROMISE Protocol May 6, 2009.
Washington D.C., USA, July 2012www.aids2012.org Economic Evaluation of the National Program to Prevent Mother-to-Child Transmission of HIV in Ghana.
Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,
Gestational diabetes mellitus (GDM), a common medical complication of pregnancy, is defined as “any degree of glucose intolerance with onset or first.
THE CORE STUDY COMPARING TWO STRATEGIES FOR ENROLLING HIV-INFECTED PREGNANT WOMEN FROM ANTENATAL CARE TO CARE AND TREATMENT SERVICES IN CAMEROON: CONTINUUM.
Programs for HIV Prevention and TreatmentIRD UMI 174 Pediatric HIV Clinical Pharmacology Program Development in Thailand Tim R. Cressey Research Associate,
A Collaborative Analysis of Data from Cohorts in Thailand, South Africa, Botswana, and the United Kingdom International Collaborative Study of Pediatric.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
HIV Drug Development in Neonates - What Now? Linda L. Lewis, M.D. Medical Officer Division of Antiviral Drug Products FDA.
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski, MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
Pediatric ID Previous presentation by Susan Schuval, MD
Evaluation of Pregnancy PBMC and Placental MtDNA in HIV-infected, HAART-treated women, compared to HIV-uninfected women* Hélène Côté* 1,2, Evelyn Maan.
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.
HIVNET 023 Sponsored by the US National Institute of Allergy and Infectious Diseases, National Institute of Health through the HIV Prevention Trials Network.
Pharmacokinetics of Saquinavir hard gel (Invirase) when combined with Atazanavir 8.11 D Prelutsky 1, P Salvato 2, R Falcon 3 1. Washington University School.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to May 2005.
Generic protocol for national population-based impact evaluation of national programs for PMTCT at 6 weeks post-partum Thu-Ha Dinh, MD., MS., US CDC/GAP.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,
Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.
CARE OF THE NEONATE. August Infants Born to Mothers with Unknown HIV Infection Status (1) Determine possible HIV exposure and need.
The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2010* * Numbers are based on reports received rather than children seen to.
1 Atazanavir (ATV) With Ritonavir (RTV) or Saquinavir (SQV) vs Lopinavir/Ritonavir (LPV/RTV) in Patients With Multiple Virologic Failures 24-Week Results.
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD,
Poster # 873 *Sharon Nachman SUNY Stony Brook Stony Brook, NY Background: RAL is a potent selective HIV-1 integrase inhibitor.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2006* *Numbers are based on reports received rather than children seen to.
PO 2726; IAS; Vicriviroc (formerly SCH ): Antiviral Activity of a Potent New CCR5 Receptor Antagonist D. Schuermann, C. Pechardscheck, R. Rouzier,
HIV DISEASE IN PREGNANCY
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
SPECIAL CONSIDERATIONS August
Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.
 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg BID –RBV.
Atazanavir Use in Pregnancy : a report of 33 cases St George’s Hospital South West London HIV & GUM Clinical Services Network Macky Natha 1, Phillip Hay.
Overview of Drug Interactions Between Brecanavir (BCV) and Other HIV Protease Inhibitors (PIs) M Shelton, S Ford, M Anderson, S Murray, J Ng-Cashin XVI.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Late maternal HIV testing, HCMC Chi K. Nguyen 1, Haily T. Pham 2, ThuVan T. Tieu 2, Chinh.
DIONE – 24 week efficacy, safety, tolerability and pharmacokinetics of DRV/r QD in treatment-naïve adolescents, 12 to
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.
Design of the RESIST Study Program Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK.
Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.
1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.
Cascade of Prevention of Mother-to-Child Transmission of HIV (PMTCT) for Option B+ Transition: Findings from a Cohort of a Nationally Representative Sample.
Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.
 Reduction in Perinatal Transmission of the HIV in Barbados after intervention with anti-retroviral therapy. M. Anne St John Consultant Paediatrician,
BARRIERS TO AND FACILITATORS FOR RETENTION OF MOTHER BABY-PAIRS IN CARE IN ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV IN EASTERN UGANDA Gerald.
Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health University of Alabama at Birmingham Birmingham, Alabama Cases From the Clinic(ians):
Comparison of Neurodevelopmental Outcomes Between HIV-Exposed, Uninfected and HIV- Unexposed Children The Tshipidi Study Presented by Jean Leidner J. Leidner.
What is known about the safety of PrEP in pregnancy? Lynda Stranix-Chibanda.
 Efficacy of Nevirapine Administration on the Mother to Child Transmission of HIV using a modified HIVNET 012 regimen. M. A St John*, Alok Kumar*, Kelly.
Loss to follow-up of HIV-infected women after delivery: The Swiss Mother and Child HIV Cohort Study Karoline Aebi-Popp, Roger Kouyos, Barbara Bertisch,
Genotype-directed dosing for Efavirenz
Emory University School of Medicine Department of Medicine
Nicole L Davis, Amanda Corbett, Joshua Kaullen,
What’s New in the Perinatal Guidelines
WITH AND WITHOUT COBICISTAT IN PREGNANCY
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
Presentation transcript:

M Mirochnick 1, A Stek 2, EV Capparelli 3, B Best 3, D Holland 3, J Connor 3, SK Burchett 4, C Hu 5, E Smith 6, JS Read 7, and PACTG 1026s Protocol Team 1 Boston Univ, Boston, MA; 2 Univ of Southern California, Los Angeles, CA; 3 UC San Diego, San Diego, CA; 4 Children’s Hospital, Boston, MA; 5 Harvard Sch of Public Health, Boston, MA; 6 NIAID, Bethesda, MD; 7 NICHD, Bethesda, MD M Mirochnick 1, A Stek 2, EV Capparelli 3, B Best 3, D Holland 3, J Connor 3, SK Burchett 4, C Hu 5, E Smith 6, JS Read 7, and PACTG 1026s Protocol Team 1 Boston Univ, Boston, MA; 2 Univ of Southern California, Los Angeles, CA; 3 UC San Diego, San Diego, CA; 4 Children’s Hospital, Boston, MA; 5 Harvard Sch of Public Health, Boston, MA; 6 NIAID, Bethesda, MD; 7 NICHD, Bethesda, MD Pharmacokinetic Parameters Study Methods Study Methods IntroductionIntroduction Clinical Characteristics k The physiologic changes of pregnancy may have a profound effect on drug disposition. We have previously shown that dosing during pregnancy with the standard lopinavir/ritonavir (LPV/r) regimen of 400 mg/100 mg twice daily results in serum concentrations ~50% lower than postpartum. 1 Optimal antiretroviral exposure during pregnancy is critical for prevention of HIV mother to child transmission and for maintenance of maternal health. LPV pharmacokinetics with a higher dose during pregnancy have not been evaluated previously. 1.Stek A, Mirochnick M, Capparelli1 E, Best B, Burchett S, Hu C, Gardella J, Elgie C, Schiffhauer J, Smith E, Read J, Tuomala R.. Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG XV International AIDS Conference, Bangkok, Thailand, July, All subjects were enrolled in P1025: “PACTG Perinatal Core Protocol” and its substudy P1026s: “Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy” 26 pregnant HIV-infected women receiving LPV/r twice daily as part of routine clinical care were studied After at least 2 weeks of stable therapy, PK evaluations were performed: During the second trimester with LPV/r dosing of 400 mg/100 mg twice daily (n=8 subjects) During the third trimester with LPV/r dosing of 533 mg/133 mg twice daily (n=26 subjects) At 2 weeks postpartum with LPV/r dosing of 533 mg/133 mg twice daily (n=22 subjects) Plasma samples collected pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose Cord blood and maternal samples collected at delivery from 23 mother-infant pairs Samples were assayed for LPV/r by a validated HPLC assay with a lower limit of quantitation of mcg/mL Area under the curve (AUC 0-12 ) was calculated with the trapezoidal rule Pharmacokinetic results were reported to their primary care givers within 2 weeks Adequate Lopinavir (LPV) Exposure Achieved with a Higher Dose During the 3rd Trimester of Pregnancy Primary Objective: To describe the pharmacokinetics of LPV during the 2 nd and 3 rd trimesters of pregnancy and postpartum Secondary Objective: To compare LPV concentrations in plasma from cord blood with those in maternal plasma at time of delivery Original Abstract Acknowledgements:Acknowledgements: The authors wish to thank the women that participated in the protocol and the staff of the participating PACTG centers. Supported by the Pediatric AIDS Clinical Trials Group funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, U01 AI41110 and by the Pediatric/Perinatal HIV Clinical Trials Network funded by the National Institute of Child Health and Human Development, National Institutes of Health, HD ObjectivesObjectives Background: Use of standard adult lopinavir/ritonavir (LPV/r) dosing (400mg/100mg) during the 3rd trimester of pregnancy results in reduced LPV exposure. Optimal antiretroviral (ARV) exposure during pregnancy is critical for prevention of HIV mother to child transmission (MTCT) and for maternal health. The goal of this analysis was to determine LPV exposure during the 3rd trimester of pregnancy and 2 weeks postpartum (PP) with a higher LPV/r dose. Methods: PACTG 1026s is an on-going, prospective, non-blinded study of ARV pharmacokinetics (PK) in HIV-infected pregnant women that includes a cohort receiving LPV/r 400mg/100mg twice daily during the 2nd trimester and 533mg/133mg twice daily during the 3rd trimester through 2 weeks postpartum. Intensive steady-state 12-hour PK profiles were performed during the 3rd trimester and at 2 weeks PP, and were optional during the 2nd trimester. Maternal and umbilical cord blood samples were obtained at delivery. LPV was measured by reverse-phase HPLC with a detection limit of 0.05 mcg/mL. Target LPV AUC was > estimated 10th percentile LPV AUC (>52mcg*hr/mL) in non-pregnant historical controls taking the standard dose (mean AUC=80mcg*hr/mL). Results: As of Sept 2005, LPV PK data were available for 23 women (7 Black, 10 Hispanic, 5 White, 1 other; median age = 31.9 yrs, median delivery weight = 79.1 kg). 2nd Trimester3rd Trimester2wk Postpartum LPV/r dose400/100 BID533/133 BID 533/133 BID Mean AUC + SD (mcg*hr/mL) Met AUC target/Total 5/8 20/23 17/18 Mean Cmin + SD (mcg/mL) AUC and Cmin were significantly lower in 3rd trimester compared to PP (p<0.005). Mean cord blood LPV concentration was mcg/mL and the mean ratio of cord blood/maternal delivery LPV concentration was (n=15). Conclusions: The higher LPV/r dose (533mg/133mg) provided adequate LPV exposure during the 3rd trimester but resulted in excessive AUC at 2 weeks PP. LPV AUC was low with standard dosing (400mg/100mg) during the 2nd trimester. These data suggest that the higher LPV/r dose should be used in 3rd trimester pregnant women, that it should be considered in 2nd trimester pregnant women, especially those who are protease inhibitor experienced, and that postpartum LPV/r dosing can be reduced to standard dosing by 2 weeks after delivery. Cord blood and maternal samples at delivery were obtained from 23 mother-infant pairs Both cord blood and maternal LPV concentrations were below the assay limit of detection in 2 mother-infant pairs LPV was measurable in cord blood and maternal samples from 21 mother-infant pairs: ConclusionsConclusions MedianRange Age at delivery (years) – 40.9 Weight at delivery (kg) – CD4+ at delivery (cells/uL) Concomitant ARV’s at delivery17 Combivir, 6 Trizivir, 6 Other Ethnicity11 Hispanic, 8 Black, 6 White, 1 Unknown The higher LPV/r dose (533mg/133mg) was tolerated well and provided adequate LPV exposure during the 3rd trimester but resulted in excessive AUC at 2 weeks PP. LPV AUC was low with standard dosing (400mg/100mg) during the 2nd trimester. LPV placental transport is poor, with a median cord blood to maternal ratio of 23%. We suggest that: The higher LPV/r dose should be used in 3rd trimester pregnant women and that it should be considered in 2nd trimester pregnant women, especially those who are protease inhibitor experienced. Postpartum LPV/r dosing can be reduced to standard dosing by 2 weeks after delivery. Since this study was performed using the recently phased out soft gel formulation (133mg/33mg per capsule), a follow up study of the new 200mg/50mg film coated tablet formulation during pregnancy is under development. Concentration – Time Figures LPV Concentration – Time Figures Median (range)2nd Trimester 400 mg/100 mg bid n=8 3 rd Trimester 533 mg/133 mg bid n=26 Postpartum 533 mg/133 mg bid n=22 AUC (mcg*hr/mL) 57.3 ( ) 87.5 ( ) ( ) C predose (mcg/mL) 2.8 ( ) 6.4 (BDL ) 11.0 ( ) C max (mcg/mL) 8.0 ( ) 9.7 ( ) 15.0 ( ) C 12 hour (mcg/mL) 2.5 ( ) 4.6 ( ) 8.6 ( ) Mark Mirochnick, MD 91 East Concord St Boston, MA Phone: Fax: Median (range) Cord blood LPV concentration (mcg/mL)0.9 ( ) Maternal LPV concentration at delivery (mcg/mL)4.9 ( ) Cord blood/maternal ratio0.23 (0.08 – 1.11) Poster # th Conference on Retroviruses and Opportunistic Infections February 5 – 8, 2006 Denver, CO, USA AUC and C pre-dose Comparisons Cord Blood and Delivery Concentrations All subjects tolerated LPV/r well, with only 3 grade III or IV toxicities noted - 1 each of hypoglycemia, pedal edema and elevated amylase Viral load at delivery was <400 copies/mL in 23/24